Enveric Biosciences, Inc. (ENVB)

Over the past six months, Enveric Biosciences' stock has experienced significant fluctuations, decreasing by 81.11%. As of February 6, 2026, the stock was trading at $2.37, a 34.7% decrease since the beginning of the year. Key events include an expanded collaboration with TOTEC Pharma, closing of a $1.5 million registered direct offering, issuance of a U.S. patent, reporting earnings after the market close with a subsequent share decline, reporting second-quarter 2025 financial results, and relocating its corporate headquarters to Cambridge, Massachusetts.

Information regarding specific demand seasonality for Enveric Biosciences' products and services is not readily available. Demand for its future products would likely be driven by disease prevalence, treatment efficacy, regulatory approvals, and market access rather than typical consumer seasonality.

Enveric Biosciences, Inc. is a biotechnology company focused on discovering and developing neuroplastogenic small-molecule therapeutics for neuropsychiatric disorders. Their primary product candidate is EB-003, a potential first-in-class neuroplastogen. The company also has other patented drug candidates from its Psybrary™ platform and previously focused on cannabinoid medicines for cancer care. Enveric Biosciences is a development-stage company and does not currently market any products.

Enveric Biosciences' corporate headquarters are located in Cambridge, Massachusetts, with additional offices in Naples, Florida, and Calgary, Alberta, Canada. The company is pursuing strategic partnerships and geographic expansion across North America and Europe. The relocation of its headquarters to Cambridge in September 2025 was intended to leverage the Greater Boston biotech hub's scientific and financial ecosystem.

Enveric Biosciences has a consensus "Hold" rating from MarketBeat, based on one buy rating and one sell rating. There is a limited amount of recent news coverage specifically addressing the company's brand reputation. The Motley Fool reported "No news articles found for Enveric Biosciences" in its news and analysis section.

As of the fourth quarter of 2025, 31 institutions hold shares of Enveric Biosciences Inc., accounting for 10.58% of the total shares. Major institutional owners include UBS Group AG, SBI Securities Co., Ltd., Danske Bank A/s, AdvisorShares Investments LLC, and Armistice Capital LLC. Key individual owners include Joseph Tucker (CEO) and Kevin Coveney.